Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Gilead withdraws bladder cancer drug in US
Gilead withdraws bladder cancer drug in US after failed trial
Gilead Sciences said on Friday it was voluntarily withdrawing the U.S. approval for Trodelvy in previously treated patients with a type of urothelial cancer after consultation with the regulator.
Gilead withdraws bladder cancer drug Trodelvy in US
Bengaluru: Gilead Sciences said on Friday it was voluntarily withdrawing its drug, Trodelvy, for previously treated patients with a type of bladder cancer after consultation with the U.S.
Gilead pulls Trodelvy's approval in bladder cancer after trial flop, FDA discussions
Trodelvy’s next big readout is EVOKE-03, which is testing the Gilead drug with Merck’s PD-1 inhibitor Keytruda in PD-L1-high NSCLC. Started in February 2023, the trial currently bears a primary completion date in January 2027.
Gilead Withdraws ADC Trodelvy in Bladder Cancer After Trial Failure
The move is a blow to Gilead’s cancer portfolio. Trodelvy, an antibody-drug conjugate granted accelerated approval for bladder cancer in 2021, failed its confirmatory trial earlier this year.
After Failed Confirmatory Trial, Gilead Withdraws US Accelerated Approval Of Trodelvy As Bladder Cancer treatment
Gilead Sciences is set to withdraw Trodelvy's accelerated approval for metastatic urothelial cancer following unsatisfactory results from the TROPiCS-04 study. However, the decision does not impact Trodelvy's other approved uses.
Drugmaker Pulls Trodelvy's Bladder Cancer Approval
Sacituzumab govitecan's (Trodelvy) accelerated approval in urothelial cancer will be voluntarily withdrawn, Gilead Sciences announced on Friday. The decision was made in consultation with the FDA and does not affect the antibody-drug conjugate's other indications, the company said.
Gilead withdraws Trodelvy in bladder cancer
The antibody drug conjugate didn’t help patients live longer in a confirmatory trial, prompting a review of its conditional approval in that indication.
ENDPOINTS NEWS
1d
Gilead pulls Trodelvy's accelerated label in bladder cancer after drug failed confirmatory study
Gilead is withdrawing the accelerated approval for its blockbuster antibody-drug conjugate Trodelvy for bladder cancer after ...
pharmaphorum
1d
Gilead's Trodelvy approved in metastatic urothelial cancer
The US pharma hopes that the
drug
will be used in those patients ... have been withdrawn in
bladder
cancer
as a result.
Gilead
said Trodelvy’s safety profile in the TROPHY study is consistent ...
Investor's Business Daily on MSN
26d
AstraZeneca Stock Dips On Surprise Miss For Gilead-Rivaling Cancer Drug
Shares of
Gilead
Sciences, which has a rival ADC approved for this form of breast
cancer
closed roughly flat at 83.99.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Trending now
Advance to World Series
Reaches tentative union deal
Boat rider arrested in FL
Postpones US tour
Hurricane Oscar forms
Philip Zimbardo dies at 91
Three Americans detained
Frozen waffles recalled
Ex-MN congressman dies
Orionids meteor shower
US deficit reaches $1.8T
Nationwide blackout in Cuba
Netanyahu's home targeted
NC breaks turnout record
School shooting report
Calif. oil refinery closure
2024 induction ceremony
PG&E shuts off power
Fire prompts evacuations
Challenges military listing
G7 ministers back Ukraine
$4M LAPD fentanyl seizure
Emergency abortion ruling
Antitrust ruling delayed
To furlough 700 workers
NK sending troops to RU?
Republicans appeal ruling
Opioid suits settlement deal
MS after game shooting
At decade-high level
Probes near miss in Austin
Bladder cancer drug pulled
Related topics
United States
Trodelvy
Feedback